Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Prognostic vs Predictive Value of ctDNA for Chemotherapy Planning and Discrepancy in Visual Presentation of Overall Survival—Reply

In this authors' reply, Kataoka, Yoshino, and Oki report treatment-by-MRD interaction tests from the up-front surgery cohort of their GALAXY analysis. For disease-free survival, the interaction HR was 0.42 (95% CI 0.15-1.18, P=0.10) in a reduced model and 0.25 (95% CI 0.08-0.75, P=0.01) in a fully adjusted model. For overall survival, interaction HRs were 0.44 (95% CI 0.07-2.90, P=0.40) and 0.35 (95% CI 0.05-2.45, P=0.29), respectively. The overall-survival interaction did not reach significance, and the disease-free survival estimates varied with covariate adjustment.

JAMA OncologyPubMed 42986612DOI 10.1001/jamaoncol.2026.4520